SCHEMBL3485924

SCHEMBL3485924

Nc1cc(C(F)(F)F)ccc1N1CCc2ccccc21

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.54
PKM P14618 1/20 0.54
KDM4E B2RXH2 3/20 0.51
LMNA P02545 3/20 0.51
NOTUM Q6P988 1/20 0.43
MAPK1 P28482 2/20 0.41
TP53 P04637 1/20 0.41
ROCK1 Q13464 1/20 0.40
MAPT P10636 3/20 0.40
GAA P10253 2/20 0.40
SRD5A1 P18405 2/20 0.40
L3MBTL1 Q9Y468 2/20 0.40
MEN1 O00255 1/20 0.40
GFER P55789 1/20 0.40
KMT2A Q03164 1/20 0.40
NPC1 O15118 2/20 0.38
RAB9A P51151 2/20 0.38
HPGD P15428 1/20 0.38
RXFP1 Q9HBX9 1/20 0.38
HSD17B10 Q99714 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL11445323 0.99 ALDH1A1 (0.53) ALDH1A1PKMKDM4ELMNANOTUM
SCHEMBL25027034 0.88 ALDH1A1 (0.43) ALDH1A1PKMKDM4ELMNANOTUM
SCHEMBL31053834 0.88 ALDH1A1 (0.43) ALDH1A1PKMKDM4ELMNANOTUM
SCHEMBL1342183 0.80 ALDH1A1 (0.51) ALDH1A1KDM4ELMNAMAPK1TP53
SCHEMBL3485666 0.80 ALDH1A1 (0.56) ALDH1A1PKMKDM4ELMNAMAPT
Hydrochloric Acid SCHEMBL10623764 0.79 ALDH1A1 (0.51) ALDH1A1KDM4ELMNAMAPK1TP53
SCHEMBL3485348 0.79 MAPT (0.58) ALDH1A1KDM4ELMNAMAPK1MAPT
SCHEMBL21929776 0.78 SRD5A1 (0.44) ALDH1A1KDM4ELMNAMAPK1TP53
SCHEMBL11453579 0.78 NOTUM (0.42) ALDH1A1KDM4ELMNANOTUMMAPK1
SCHEMBL8938754 0.77 LMNA (0.53) ALDH1A1KDM4ELMNANOTUMMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2666481-B9 Method of regulating phosphorylation of sr protein and antiviral agents comprising sr protein activity regulator as the active ingredient HAGIWARA MASATOSHI (JP) 2019-05-22 EP disclosed
EP-2666481-B1 Method of regulating phosphorylation of sr protein and antiviral agents comprising sr protein activity regulator as the active ingredient HAGIWARA MASATOSHI (JP) 2018-11-14 EP disclosed
EP-1712242-B1 METHOD OF REGULATING PHOSPHORYLATION OF SR PROTEIN AND ANTIVIRAL AGENTS COMPRISING SR PROTEIN ACTIVITY REGULATOR AS THE ACTIVE INGREDIENT HAGIWARA MASATOSHI (JP) 2018-05-30 EP disclosed
EP-1712242-B1 METHOD OF REGULATING PHOSPHORYLATION OF SR PROTEIN AND ANTIVIRAL AGENTS COMPRISING SR PROTEIN ACTIVITY REGULATOR AS THE ACTIVE INGREDIENT HAGIWARA MASATOSHI (JP) 2018-05-30 EP disclosed
US-8816089-B2 Methods for controlling SR protein phosphorylation, and antiviral agents whose active ingredients comprise agents that control SR protein activity Hagiwara, Masatoshi (JP) 2014-08-26 US disclosed
US-8816089-B2 Methods for controlling SR protein phosphorylation, and antiviral agents whose active ingredients comprise agents that control SR protein activity Hagiwara, Masatoshi (JP) 2014-08-26 US disclosed
US-8816089-B2 Methods for controlling SR protein phosphorylation, and antiviral agents whose active ingredients comprise agents that control SR protein activity Hagiwara, Masatoshi (JP) 2014-08-26 US disclosed
CN-101837125-B Method of regulating phosphorylation of PTH protein and antiviral agents comprising SR protein activity regulator as the active ingredient HAGIWARA MASATOSHI 2014-02-26 CN disclosed
EP-2666481-A2 Method of regulating phosphorylation of sr protein and antiviral agents comprising sr protein activity regulator as the active ingredient HAGIWARA, Masatoshi (JP) 2013-11-27 EP disclosed
CN-1921885-B Use of an aniline derivative or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of a viral infection in a patient HAGIWARA MASATOSHI 2013-06-12 CN disclosed
US-20070135367-A1 Broad spectrum antiviral including against SARS (severe acute respiratory syndrome), DNA viruses and herpes viruses; Ser-Arg (SR), SR proteins are RNA-binding proteins; compounds are SRPK inhibitors such as 1-piperidino-2-(pyridin-4-ylcarbonylamino)-4-trifluoromethylbenzene HAGIWARA, MASATOSHI (JP) 2007-06-14 US disclosed
CN-1921885-A Method for controlling phosphorylation of SR protein and antiviral agent comprising SR protein activity controller as active ingredient HAGIWARA MASATOSHI (JP) 2007-02-28 CN disclosed
EP-1712242-A1 METHOD OF REGULATING PHOSPHORYLATION OF SR PROTEIN AND ANTIVIRAL AGENTS COMPRISING SR PROTEIN ACTIVITY REGULATOR AS THE ACTIVE INGREDIENT HAGIWARA, Masatoshi (JP) 2006-10-18 EP disclosed
US-4764616-A ANALGESIC, ANTIPHYCHOTIC HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) 1988-08-16 US disclosed
US-4761412-A Benzopyrrolobenzodiazepines and quinobenzodiazepines useful for the treatment of psychoses HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) 1988-08-02 US disclosed
US-4761411-A Dihydrobenzopyrrolobenzodiazepines useful for treating pyschoses HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) 1988-08-02 US disclosed
US-4723003-A ANTIPSYCHOTIC AGENTS, ANALGESICS HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) 1988-02-02 US disclosed
US-4723007-A ANALGESICS, ANTIPSYCHOTIC AGENTS; INTERMEDIATES FOR PROCESSING HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) 1988-02-02 US disclosed
US-4663453-A Benzo[b]pyrrolo[3,2,1-jk][1,4]benzodiazepines having dopamine receptor activity HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) 1987-05-05 US disclosed
EP-0129692-A2 Dibenzodiazepin derivatives, a process for their preparation and their use as medicaments HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) 1985-01-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070135367-A1 Broad spectrum antiviral including against SARS (severe acute respiratory syndrome), DNA viruses and herpes viruses; Ser-Arg (SR), SR proteins are RNA-binding proteins; compounds are SRPK inhibitors such as 1-piperidino-2-(pyridin-4-ylcarbonylamino)-4-trifluoromethylbenzene SRPK1, SARS1, SRPK3 ALDH1A1 4791/4885PKM 885/4885KDM4E 529/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.